Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma

Elisabeth Höring1,2,3, Arnau Montraveta3, Simon Heine1

  • 1Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany.

Insights

Combining fatty acid synthase inhibitors and Dinaciclib synergistically targets the NOXA/MCL1 axis, inducing apoptosis and inhibiting mantle cell lymphoma (MCL) progression. This dual-targeting strategy shows promise for MCL therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Imbalances in BCL2 protein family composition drive mantle cell lymphoma (MCL) development and treatment resistance.
  • BCL2 family proteins represent promising therapeutic targets in MCL.

Purpose of the Study:

  • To investigate the efficacy of dual targeting the NOXA/MCL1 axis in MCL.
  • To evaluate the combination of fatty acid synthase (FAS) inhibitors and the CDK inhibitor Dinaciclib for MCL treatment.

Main Methods:

  • Utilized cell lines and primary MCL cells for in vitro studies.
  • Employed a mouse model to assess in vivo tumor progression.
  • Combined FAS inhibitors (for NOXA stabilization) with Dinaciclib (for MCL1 reduction).

Main Results:

  • The combination therapy synergistically induced apoptosis in MCL cell lines and primary cells.
  • Tumor progression was almost completely inhibited in a mouse model.
  • Apoptosis induction was dependent on NOXA and correlated with the NOXA/MCL1 ratio.

Conclusions:

  • The NOXA/MCL1 balance is critical for effective apoptosis induction in MCL.
  • Dual targeting of the NOXA/MCL1 axis represents a potent therapeutic strategy for mantle cell lymphoma.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K